Clinical outcomes, serum IgG changes, and follow-up observations in the treatment of anti-AChR antibody-positive generalized myasthenia gravis with Efgartigimod - PubMed
4 days ago
- #Myasthenia Gravis
- #Efgartigimod
- #Immunotherapy
- Efgartigimod treatment showed rapid clinical improvement in anti-AChR positive generalized myasthenia gravis (gMG) patients.
- 100% of patients achieved clinically meaningful reduction (CMR) in MG-ADL scores, and 87.5% in QMG scores.
- Serum IgG levels significantly decreased post-treatment, while IgA and IgM levels remained unchanged.
- Follow-up (190-414 days) showed 6 patients achieved minimal manifestation status with only grade 1 adverse events.
- One patient experienced symptom recurrence after discontinuing treatment, another had exacerbation due to respiratory infection.
- Efgartigimod, combined with immunosuppressants, helps maintain long-term disease control.